CAM
SGYP

Cormorant Asset Management’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Cormorant Asset Management’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,200,000
Closed -$5.34M – 75
2017
Q2 		$5.34M Hold
1,200,000
– – 0.89% 29
2017
Q1 		$5.59M Sell
1,200,000
-300,000
-20% -$1.74M 0.81% 39
2016
Q4 		$9.13M Buy
+1,500,000
New +$7.84M 1.23% 27

Other funds holding SGYP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cormorant Asset Management's SGYP Position: Q3 2017 in Review

Cormorant Asset Management sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q3 2017, closing a stake of 1,200,000 shares — an estimated $5.34M sold.

Cormorant Asset Management first reported a position in SGYP in Q4 2016 and held it in 3 quarters. The position peaked at $9.13M in Q4 2016. 143 funds tracked by Wall St. Rank hold SGYP as of Q3 2017.

  • Cormorant Asset Management reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q3 2017 after selling out during the quarter.
  • Cormorant Asset Management sold 1,200,000 Synergy Pharmaceuticals, Inc Common Stock shares in Q3 2017, an estimated $5.34M.
  • Cormorant Asset Management first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q4 2016 and held it in 3 quarters.
  • Cormorant Asset Management's Synergy Pharmaceuticals, Inc Common Stock position peaked at $9.13M in Q4 2016.
  • 143 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q3 2017.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.